In this week’s Xtalks Life Science podcast episode, Ayesha and the team spoke with the co-founders and co-CEOs of Amylyx, Joshua Cohen and Justin Klee, and Amylyx’s General Manager of Canada Chris Aiello, about the recent FDA approval of the company’s ALS drug Relyvrio.
Amylyx is a pharmaceutical company focused on the development of therapies for neurodegenerative diseases. On September 29th this year, Amylyx received FDA approval for its oral, fixed dose medication Relyvrio for the treatment of adults with amyotrophic lateral sclerosis (ALS). A few months earlier, the medication had received conditional approval in Canada, where it is marketed under the brand name Albrioza. To hear more about Relyvrio’s approval, including how the Ice Bucket Challenge for ALS helped in the drug’s development, and Amylyx’s continuing work in neurodegenerative diseases, tune into the episode.
Read the full article here:
Relyvrio Approved as ALS Treatment by the FDA
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a commentJOIN LOGIN